Adacel
STN: BL 125111
Proper Name: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed
Tradename: ADACEL
Manufacturer: Sanofi Vaccines Canada Ltd
Adacel is a vaccine indicated for:
- Active booster immunization against tetanus, diphtheria and pertussis. Adacel is approved for use in persons 10 through 64 years of age.
- Immunization during the third trimester of pregnancy to prevent pertussis in infants younger than 2 months of age.
- August 26, 2026 - Approval Letter - Adacel
- July 30, 2026 Approval Letter - ADACEL
- May 11, 2023 Approval Letter - Adacel
- BLA Clinical Review Memorandum (125111/904) - ADACEL
- January 9, 2023 Statistical Review - ADACEL
- January 9, 2023 Approval Letter - Adacel
- December 28, 2020 Approval Letter - Adacel
- January 11, 2019 Summary Basis for Regulatory Action - Adacel
- January 11, 2019 Approval Letter - Adacel
To include re-administration in adolescents and adults following a previous dose. - September 29, 2017 Approval Letter - Adacel
- Supporting Documents older than three years - Adacel